Envoy Medical, Inc.

Company Overview

Business Model: Envoy Medical, Inc. is a hearing health company dedicated to developing and commercializing innovative medical technologies across the hearing loss spectrum. Its core value proposition is centered on fully implanted hearing devices that leverage the ear's natural anatomy to capture sound, eliminating the need for external or sub-dermal artificial microphones. While currently generating limited revenue from its Esteem Fully Implanted Active Middle Ear Implant and replacement components, the company's strategic focus and primary future revenue generation mechanism is the investigational Acclaim Cochlear Implant, pending successful FDA approval and commercialization.

Market Position: Envoy Medical, Inc. operates in the competitive medical device industry, specifically targeting the hearing loss market. Its Esteem Fully Implanted Active Middle Ear Implant holds a unique position as the only FDA-approved fully implanted active hearing implant in the U.S. market, though its commercial traction has been hindered by reimbursement classification. The company's investigational Acclaim Cochlear Implant is positioned to disrupt the existing cochlear implant market, which is currently dominated by three main incumbents: Cochlear Ltd., Advanced Bionics (Sonova), and Med-El. Envoy Medical, Inc. aims to differentiate itself through its fully implanted design, which offers advantages over traditional partially implanted devices, potentially appealing to a significant unserved market segment. The Acclaim Cochlear Implant received Breakthrough Device Designation from the FDA in 2019.

Recent Strategic Developments:

• Acclaim Cochlear Implant Clinical Trial Progress: Envoy Medical, Inc. completed enrollment of all 56 patients in its pivotal clinical study for the Acclaim Cochlear Implant on March 10, 2026. This study is designed to demonstrate the safety and efficacy of the device for severe-to-profound sensorineural hearing loss.
• FDA Approval Timeline: The company anticipates obtaining FDA approval for the Acclaim Cochlear Implant in late 2027 or early 2028, contingent on the successful completion of the pivotal study and the FDA's review process.
• Capital Raising: In February 2026, Envoy Medical, Inc. completed a public offering, securing approximately $27.730 million in net proceeds. This offering also provides potential for an additional $48.000 million in gross proceeds from the full exercise of Series A-1 Warrants and Series A-2 Warrants, intended to fund operations during the clinical trial.
• Debt Extinguishment: On August 25, 2025, GAT Funding, LLC forgave all outstanding principal and accrued interest on Term Loans in exchange for a $0.100 million payment from Envoy Medical, Inc. This resulted in a $27.879 million gain on extinguishment, recorded as a capital contribution.
• Warrant Extension: As part of a Voting and Extension Agreement, the expiration date of the Term Loan Warrants was extended to December 31, 2028.

Geographic Footprint: Envoy Medical, Inc.'s primary operations are in the United States, with its principal office and final manufacturing facility located in White Bear Lake, Minnesota. The company also maintains a small sales office in Ausbach, Germany. Future international expansion plans include pursuing the Conformité Européenne mark (CE Mark) in the European Union shortly after FDA approval for the Acclaim Cochlear Implant, with subsequent consideration of markets such as Australia, Brazil, and parts of Asia.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: -262.7%
• Operating Margin: -92.4%
• Net Margin: -98.6%

Investment in Growth:

• R&D Expenditure: $12.486 million (5180.9% of revenue)
• Capital Expenditures: $0.179 million
• Strategic Investments: The company's primary strategic investment is in the research and development, and clinical trials of the Acclaim Cochlear Implant. Specific major investment initiatives beyond R&D and capital expenditures are not separately detailed.

Business Segment Analysis

Hearing Segment

Financial Performance:

• Revenue: $0.241 million (+7.1% YoY)
• Operating Margin: -92.4% (reflecting consolidated operating loss as the sole reportable segment)
• Key Growth Drivers: Current revenue is primarily from the Esteem Fully Implanted Active Middle Ear Implant and its replacement components. Future growth is entirely contingent on the successful FDA approval and subsequent commercialization of the Acclaim Cochlear Implant.

Product Portfolio:

• Esteem Fully Implanted Active Middle Ear Implant (Esteem FI-AMEI): FDA-approved since 2010, this device is the only fully implanted active hearing implant available in the U.S. market. It utilizes an implanted sensor to capture sound energy from the ossicular chain. Despite its unique status, commercial adoption has been limited due to its classification as a hearing aid by Centers for Medicaid and Medicare Services (CMS), impacting reimbursement. Approximately 1,000 devices have been implanted globally, providing extensive experience with the underlying sensor technology.
• Acclaim Cochlear Implant (Acclaim CI): An investigational, fully implanted cochlear implant designed to treat severe-to-profound sensorineural hearing loss that is not adequately addressed by hearing aids. A key differentiator is its piezoelectric sensor, which is implanted in the middle ear to capture sound, eliminating the need for external components. The device also features an implanted sound processor and power source, with the battery pack expected to be replaced every 8-12 years via a less invasive surgical procedure. The Acclaim Cochlear Implant received Breakthrough Device Designation from the FDA in 2019, and its pivotal clinical study completed patient enrollment on March 10, 2026.

Market Dynamics:

• Competitive Positioning within Segment: The Acclaim Cochlear Implant is positioned to compete against established players like Cochlear Ltd., Advanced Bionics (Sonova), and Med-El. Its fully implanted design is a significant competitive advantage, targeting individuals who are reluctant to adopt traditional partially implanted cochlear implants due to the presence of external components.
• Key Customer Types and Market Trends: The target demographic for the Acclaim Cochlear Implant includes adults with severe-to-profound sensorineural hearing loss. The estimated addressable market in the U.S. is approximately 2.8 million adults who could qualify for a cochlear implant. Industry trends indicate a growing focus on usability, connectivity, lifestyle integration, miniaturization, and expanding clinical candidacy criteria (e.g., for single-sided deafness and broader word recognition scores).

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No share repurchases were reported for the three months ended December 31, 2025.
• Dividend Payments: $1.819 million was paid in dividends to preferred stockholders in 2025.
• Dividend Yield: Not applicable for Class A Common Stock, as the company does not anticipate declaring or paying any cash dividends on these shares for the foreseeable future, intending to retain all available funds for business development and growth.
• Future Capital Return Commitments: The company's current strategy prioritizes reinvestment in the business, particularly the development and commercialization of the Acclaim Cochlear Implant.

Balance Sheet Position:

• Cash and Equivalents: $3.739 million (as of December 31, 2025)
• Total Debt: $0 million (as of December 31, 2025, following the extinguishment of Term Loans from GAT Funding, LLC)
• Net Cash Position: $3.739 million (as of December 31, 2025)
• Credit Rating: Not disclosed in the filing.
• Debt Maturity Profile: All Term Loans from GAT Funding, LLC were extinguished on August 25, 2025.

Cash Flow Generation:

• Operating Cash Flow: $(18.201) million (used in operating activities for the year ended December 31, 2025)
• Free Cash Flow: $(18.380) million (calculated as operating cash flow less capital expenditures)
• Cash Conversion Metrics: Specific cash conversion metrics were not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: Envoy Medical, Inc. conducts all final manufacturing operations at its facility in White Bear Lake, Minnesota. The company relies on a limited number of technicians and specialized critical equipment. To support future commercialization, plans include expanding manufacturing capacity and implementing additional shifts. The operational philosophy for the Acclaim Cochlear Implant's initial market release emphasizes quality over rapid volume growth.

Supply Chain Architecture: Envoy Medical, Inc. utilizes third-party suppliers for the manufacturing of some critical sub-assemblies, a strategy that helps reduce the need for extensive capital investment. Suppliers are rigorously selected, monitored for regulatory adherence, and undergo qualification and periodic reviews and audits to ensure performance. Key Suppliers & Partners:

• Component Suppliers: Certain critical components are sourced from single-source suppliers. The company aims to mitigate associated risks by maintaining sufficient inventory levels and planning for the qualification of alternative suppliers.
• Manufacturing Partners: Third-party entities are engaged for sub-assembly manufacturing.
• Technology Partners: Not explicitly detailed as named entities in the filing.

Facility Network:

• Manufacturing: The primary manufacturing and R&D operations are located at the 13,500 square foot facility in White Bear Lake, Minnesota.
• Research & Development: Integrated within the White Bear Lake, Minnesota facility.
• Distribution: While not yet fully established, the company plans to develop robust distribution capabilities upon obtaining FDA approval for the Acclaim Cochlear Implant.
• Office Space: An additional 1,100 square feet of office space is leased in Ausbach, Germany, serving as a sales office.

Operational Metrics: Specific quantitative operational metrics such as capacity utilization, efficiency measures, or quality indicators were not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Upon receiving Premarket Approval (PMA) for the Acclaim Cochlear Implant, Envoy Medical, Inc. plans a commercialization strategy focused on quality rather than rapid expansion, aiming to establish a strong market presence. Distribution Channels:

• Direct Sales: The company intends to strategically select approximately 30 surgical sites, primarily otologists and neurotologists, across the United States for initial training and implantation upon commercialization. The plan is to subsequently add around 30 new sites annually, targeting a network of approximately 150 active implanting sites.
• Channel Partners: Audiologists who traditionally work with hearing aid patients are expected to play a crucial role in identifying and referring potential Acclaim Cochlear Implant candidates to surgical sites.
• Digital Platforms: Specific digital sales or e-commerce initiatives were not explicitly detailed in the filing.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: The strategy involves building strong relationships with both surgical teams and audiologists at selected sites to ensure understanding and differentiation of the Acclaim Cochlear Implant.
• Strategic Partnerships: While clinical trial collaborations exist (e.g., Mayo Clinic), specific named strategic partnerships for commercial customer relationships were not detailed.
• Customer Concentration: The initial go-to-market strategy targets a relatively small community of specialized surgical professionals.

Geographic Revenue Distribution:

• United States: Currently the primary market for revenue generation and the immediate focus for the Acclaim Cochlear Implant's commercialization.
• Growth Markets: Envoy Medical, Inc. anticipates pursuing the CE Mark in the European Union shortly after FDA approval, with future plans to expand into other international markets such as Australia, Brazil, and parts of Asia, contingent on regulatory approvals and reimbursement availability.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The hearing loss market is highly competitive, dynamic, and susceptible to new product introductions. Hearing loss affects approximately 15% of the adult U.S. population, with sensorineural hearing loss accounting for about 90% of cases. The global economic burden of untreated hearing loss is estimated at $750 billion annually. Recent trends in the cochlear implant industry include a focus on aesthetics, user-friendliness, connectivity, environmental robustness, reliability, and the expansion of clinical candidacy criteria (e.g., for single-sided deafness and improved word recognition scores).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Cochlear Ltd.: The leading cochlear implant manufacturer, holding approximately 65% of the global market share, with a market capitalization of approximately $12 billion USD as of December 31, 2025.
• Advanced Bionics (Sonova): A major incumbent in the cochlear implant market.
• Med-El: A significant incumbent in the cochlear implant market.
• Oticon Medical (Demant): Its cochlear implant business was acquired by Cochlear Ltd. Emerging Competitive Threats:
• The company faces threats from new market entrants, disruptive technologies, or alternative therapies that could render its products obsolete or uncompetitive. Competitors may gain an advantage through faster product development, quicker regulatory approvals, or lower pricing strategies. Competitive Response Strategy: Envoy Medical, Inc. believes the fully implanted nature of the Acclaim Cochlear Implant will be a compelling competitive advantage for physicians and patients. The company plans to make substantial investments in patient advertising, provider education and training, distribution capabilities, and strategic relationships with physicians to capitalize on these advantages and capture market share, particularly among the currently unserved patient population.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Unpredictability of Product Development: The medical device development process is inherently uncertain, with no guarantee that the Breakthrough Device Designation will expedite approval or that the Acclaim Cochlear Implant will ultimately receive FDA approval.
• Competition: Intense competition from larger, more established medical device companies with greater financial and operational resources, existing distribution networks, and entrenched relationships with healthcare professionals.
• Market Acceptance: The Acclaim Cochlear Implant may not achieve sufficient market acceptance if healthcare professionals do not recommend it or if patients are slow to adopt the new technology.
• Demand Volatility: Fluctuations in demand for the Acclaim Cochlear Implant could arise from factors such as market acceptance, perceived clinical safety and performance, the emergence of competing products, adverse medical side effects, changes in regulatory policies, or the availability of reimbursement.
• Healthcare Reform: Ongoing and future legislative and regulatory changes in healthcare systems, particularly those focused on cost containment, could limit coverage or reduce reimbursement for the company's products, adversely affecting profitability.
• Technology Disruption: Risk of new or alternative therapies and technologies emerging that could better treat or cure hearing loss, potentially rendering Envoy Medical, Inc.'s products obsolete.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on third-party suppliers for critical sub-assemblies and single-source suppliers for certain components creates vulnerability to supply shortages, increased costs, and quality control issues.
• Capacity Constraints: Significant increases in production rates will be required for clinical trials and commercialization, necessitating expansion of manufacturing capacity and additional shifts.
• Manufacturing Defects: The Acclaim Cochlear Implant, being a new product, carries the risk of latent design or manufacturing defects that could lead to unexpected performance, adverse patient effects, costly redesigns, and damage to the company's reputation and financial results. Internal Control Weaknesses:
• Material Weaknesses in Internal Control Over Financial Reporting: Identified deficiencies, including insufficient accounting personnel, lack of formal risk assessment, and inadequate design and maintenance of controls, pose a reasonable possibility of material misstatements in financial reporting and could adversely affect investor confidence. Clinical Trial Risks:
• Clinical Failure: Clinical failure can occur at any stage of development. Early clinical experience does not guarantee future results, and potential limitations or complications may not be fully revealed until broader patient use.
• Regulatory Delays: Delays in obtaining FDA approval for the Acclaim Cochlear Implant would hinder the expansion of corporate infrastructure, development of distribution capabilities, and implementation of training, potentially requiring significant additional capital. Human Capital Risks:
• Key Personnel Dependency: The company is highly dependent on key members of its executive management team, and the inability to retain these individuals could impede business plans and growth strategies.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Uncertainty: The company has a history of operating losses and negative cash flow, leading to an explanatory paragraph in its financial statements regarding substantial doubt about its ability to continue as a going concern, necessitating substantial additional funding.
• Funding Availability: The need to raise substantial additional funding, which may not be available on acceptable terms or at all, could force the company to curtail, delay, or discontinue product development efforts.
• Dilution: Future equity offerings to raise capital would result in dilution to existing stockholders' ownership interests.
• Reimbursement Uncertainty: Successful commercialization of the Acclaim Cochlear Implant is dependent on governmental authorities and health insurers establishing coverage, adequate reimbursement levels, and favorable pricing policies.
• Global Economic Conditions: Unfavorable global economic conditions, including inflationary pressures, rising interest rates, and supply chain disruptions, could adversely affect the company's business, financial condition, and ability to access capital. Regulatory & Compliance Risks:
• FDA Approval: The Acclaim Cochlear Implant is a Class III medical device requiring Premarket Approval (PMA), a rigorous and lengthy process with uncertain timelines and outcomes.
• Post-market Regulation: After approval, the company remains subject to extensive post-market regulatory requirements (e.g., Quality System Regulations, adverse event reporting), with non-compliance potentially leading to significant enforcement actions.
• Fraud and Abuse Laws: Compliance with federal, state, and foreign anti-kickback, false claims, and transparency laws is critical, as violations can result in substantial civil, criminal, and administrative penalties.
• Data Privacy and Security Laws: Adherence to numerous state, federal, and foreign data privacy and security laws (e.g., HIPAA, GDPR) is required, with evolving regulations and potential for significant penalties for non-compliance or data breaches.
• Legal Proceedings: Involvement in various legal proceedings, including a stockholder lawsuit seeking significant damages, can divert management attention and incur substantial costs.
• Nasdaq Listing Compliance: Failure to meet Nasdaq's continued listing requirements, such as minimum bid price or market value of listed securities, could result in delisting, negatively impacting stock price and liquidity.

Geopolitical & External Risks

Geopolitical Exposure:

• Geographic Dependencies: Not explicitly detailed, but global events such as wars and armed conflicts could impact supply chains and overall economic conditions.
• Trade Relations: Not explicitly detailed, but general risks associated with international trade policies and relations could affect global expansion plans.
• Sanctions & Export Controls: Not explicitly detailed, but compliance with international trade restrictions and sanctions would be necessary for global operations.

Innovation & Technology Leadership

Research & Development Focus: Envoy Medical, Inc.'s research and development efforts over the next several years are primarily directed towards enhancing the existing design of the Acclaim Cochlear Implant. A core focus is on improving product quality and reliability during the initial years of market release. Additionally, the R&D team is dedicated to developing robust software and user interfaces to optimize the experience for both patients and healthcare professionals. Core Technology Areas:

• Sensor Technology: The company's proprietary piezoelectric sensor, implanted in the middle ear, is a foundational technology. It is designed to capture sound by leveraging the ear's natural anatomy, distinguishing it from devices that rely on external or sub-dermal microphones. This technology underpins both the Esteem Fully Implanted Active Middle Ear Implant and the Acclaim Cochlear Implant.
• Fully Implanted Devices: A strategic emphasis is placed on developing fully implanted devices that eliminate external components, aiming to improve patient usability, independence, and overall quality of life.
• Rechargeable Battery Technology: For the Acclaim Cochlear Implant, a key area of focus is the implanted rechargeable battery, engineered to provide several days of power between charges. The design allows for a less invasive surgical procedure for battery pack replacement, expected every 8-12 years. Innovation Pipeline:
• The Acclaim Cochlear Implant is the company's lead product candidate, currently undergoing pivotal clinical trials.
• Future product evolution is centered on iterative improvements and enhancements to the Acclaim Cochlear Implant's design and functionality.
• While not a current priority, the Esteem Fully Implanted Active Middle Ear Implant could benefit from future upgrades to its power source and chip design if reimbursement policies become more favorable.

Intellectual Property Portfolio: Envoy Medical, Inc. protects its intellectual property through a combination of patents, copyrights, trademarks, and trade secrets.

• Patent Strategy: As of March 2, 2026, the company holds rights to 40 issued U.S. patents, with estimated expiration dates between 2028 and 2043. It also has 9 pending U.S. patent applications, 48 issued foreign patents, and 26 pending foreign and international patent applications. These patents cover various aspects of the current Acclaim Cochlear Implant system and future product concepts.
• Licensing Programs: The filing does not explicitly detail current licensing programs for revenue generation or strategic partnerships.
• IP Litigation: There is no active litigation involving the company's patents or other intellectual property rights, nor has it received any notices of patent infringement. However, the company acknowledges the potential need to enforce or defend its intellectual property rights in the future.

Technology Partnerships:

• Strategic Alliances: While the company engages in clinical trial collaborations (e.g., with Mayo Clinic for the Early Feasibility Study), specific named strategic technology alliances or research collaborations were not explicitly detailed in the filing.
• Research Collaborations: Not explicitly detailed.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's ability to execute its business plan and growth strategies is highly dependent on the continued services of its key senior management team members. Specific succession planning or leadership development initiatives were not explicitly detailed in the filing.

Board Composition:

• Chairman: Charles R. Brynelsen, who brings extensive experience in the medical device industry, including senior leadership roles at Abbott Vascular and Medtronic, and as a Venture Partner at SpringRock Ventures.
• Directors:
  • Michael Crowe, with decades of experience in medical device operations, including Senior Vice President Operations for Bioventus LLC and Abbott Vascular.
  • Mona Patel, possessing over 30 years of experience in medical device marketing, market development, clinical education, and mergers and acquisitions at companies like Boston Scientific and Guidant.
  • Janis Smith-Gomez, with over 30 years of experience in marketing and innovation, holding leadership positions at Johnson & Johnson, Mars, Kraft Foods, and PepsiCo.
  • Susan J. Kantor, who has served since March 2021, bringing extensive background and expertise in global financial and tax matters, including experience as an Advisory Partner for PwC and CFO/Treasurer of PRTM Management Consultants. Ms. Kantor qualifies as a "financial expert" and serves as the Chair of the Audit Committee.
• Independence, Expertise Areas, Committee Structure: The Board comprises individuals with diverse expertise in medical device management, operations, marketing, finance, and regulatory compliance. The Audit Committee is chaired by a financial expert.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of December 31, 2025, Envoy Medical, Inc. had approximately 43 full-time employees and 4 part-time employees.
• Geographic Distribution: The majority of employees are located in the United States, with a small presence in Germany.
• Skill Mix: A significant portion of the workforce possesses technical backgrounds, including advanced engineering or scientific degrees.

Talent Management: Acquisition & Retention:

• Hiring Strategy: The company expects to hire additional accounting and financial reporting personnel as part of its remediation efforts for identified material weaknesses in internal control.
• Retention Metrics: Specific employee turnover rates or retention metrics were not explicitly disclosed in the filing.
• Employee Value Proposition: Envoy Medical, Inc. considers its investment in human capital crucial for success, fostering an inclusive culture based on trust and mutual respect. The company believes its relatively small size allows employees to feel a direct sense of pride and ownership in their work and mission. Employee compensation and benefits have been increased since 2022 to enhance retention and attract new talent in a competitive market.

Diversity & Development:

• Diversity Metrics: Specific representation data across key demographics was not explicitly disclosed in the filing.
• Development Programs: Details on formal training, leadership development, or career advancement programs were not explicitly provided.
• Culture & Engagement: The company emphasizes a highly collaborative work environment, aiming for employees to feel engaged and connected to the company's mission.

Environmental & Social Impact

Environmental Commitments:

• Climate Strategy: Specific climate strategy, emissions targets, or carbon neutrality commitments were not explicitly detailed in the filing.
• Renewable Energy: Information regarding clean energy adoption or sourcing strategies was not explicitly detailed.

Supply Chain Sustainability:

• Supplier Engagement: The company requires its third-party suppliers to adhere to all applicable regulations and monitors their performance through qualification and periodic reviews and audits. Further details on broader ESG requirements or supplier diversity programs were not explicitly provided.
• Responsible Sourcing: Information on responsible materials sourcing or conflict minerals compliance was not explicitly detailed.

Social Impact Initiatives:

• Community Investment: Specific philanthropic programs or local community support initiatives were not explicitly detailed in the filing.
• Product Impact: Envoy Medical, Inc.'s core mission is to provide innovative medical technologies to address hearing loss, a debilitating human condition correlated with increased anxiety, depression, social isolation, and other health issues. The company's products aim to improve patients' access, usability, independence, and quality of life, thereby contributing to social well-being.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Specific seasonal trends in demand patterns were not explicitly detailed in the filing.
• Economic Sensitivity: The company's financial performance is susceptible to general global economic conditions. A recession or market correction could lead to reduced disposable income, potentially decreasing sales of the Esteem Fully Implanted Active Middle Ear Implant and replacement components as customers and patients may defer treatment due to financial considerations.
• Industry Cycles: While not explicitly detailed, the medical device industry can be influenced by broader economic cycles and healthcare spending trends.

Planning & Forecasting:

• Demand forecasting approach, inventory management, capacity planning: The company intends to maintain sufficient levels of inventory to mitigate potential supply disruptions. Further details on specific demand forecasting methodologies or capacity planning strategies were not explicitly provided.

Regulatory Environment & Compliance

Regulatory Framework:

• Industry-Specific Regulations: Envoy Medical, Inc.'s products and operations are subject to extensive regulation by the FDA and other federal and state authorities in the U.S., as well as comparable authorities in the European Economic Area (EEA) and other countries. The Acclaim Cochlear Implant is classified as a Class III medical device, necessitating Premarket Approval (PMA) from the FDA, a process that is more demanding than 510(k) clearance and can take several years.
• International Compliance: The company plans to pursue the Conformité Européenne mark (CE Mark) in the European Union shortly after FDA approval, and subsequently seek regulatory approvals in other international markets. Trade & Export Controls:
• Export Restrictions: Not explicitly detailed in the filing.
• Sanctions Compliance: Not explicitly detailed in the filing.

Legal Proceedings:

• Material Litigation: As of November 14, 2023, Envoy Medical, Inc. is a defendant in a lawsuit filed by Atlas Merchant Capital SPAC Fund I LP in the Delaware Court of Chancery. The plaintiff alleges it was improperly prevented from redeeming shares and seeks approximately $9.4 million in damages, along with interest and fees. Envoy Medical, Inc. believes the lawsuit is meritless and is vigorously defending the matter. A motion to dismiss was partially granted on March 3, 2025, narrowing the scope of the litigation.
• Regulatory Investigations: No material regulatory investigations were explicitly disclosed in the filing.
• Settlement Exposures: Envoy Medical, Inc. maintains business liability insurance to cover litigation costs exceeding $50,000. As of December 31, 2025, no accruals for potential losses related to existing or pending litigation claims have been recorded, as management determined that no potential loss is probable and reasonably estimable.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The company's effective tax rate differs from the federal statutory rate primarily due to the tax expense impact of nondeductible equity compensation, other permanent differences, tax credits, state taxes, and a full valuation allowance.
• Geographic Tax Planning: Envoy Medical, Inc. has not recorded deferred income taxes on certain outside basis differences related to its investment in its German subsidiary, as the earnings are considered indefinitely reinvested to support foreign operations.
• Tax Reform Impact: The One Big Beautiful Bill Act (OBBA), enacted on July 4, 2025, introduced immediate expensing of domestic research and development (R&D) costs and reinstated 100% bonus depreciation. Envoy Medical, Inc. has elected to immediately expense domestic R&D expenditures and will amortize previously capitalized costs over the years ended December 31, 2025, and December 31, 2026. These changes did not materially impact the company's financial statements for the year ended December 31, 2025.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, the company had federal tax NOL carryforwards of $190.278 million (some expiring 2026-2035, others not expiring) and state NOL carryforwards of $32.182 million (expiring 2026-2035).
• Research and Development (R&D) Credits: As of December 31, 2025, federal R&D credits of $1.442 million and state R&D credits of $0.818 million are available, expiring 2026-2035.
• Valuation Allowance: A full valuation allowance of $50.163 million was recorded against net deferred tax assets as of December 31, 2025, due to the uncertainty of realizing related benefits, primarily driven by a history of operating losses.
• Cancellation of Debt Income (CODI): In 2025, the company recognized $32.012 million of CODI for U.S. tax purposes due to the extinguishment of Term Loans.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Envoy Medical, Inc. maintains business liability insurance designed to cover litigation costs exceeding $50,000.
• Risk Transfer Mechanisms: Beyond the disclosed business liability insurance, other specific risk transfer mechanisms were not explicitly detailed in the filing.